Prostate neoplasm
MONDO:0021259A neoplasm (disease) that involves the prostate gland.
Also known as: neoplasm of prostate, neoplasm of prostate gland, neoplasm of the prostate, prostate gland neoplasm, prostate gland neoplasm (disease), prostate gland tumor, prostate gland tumour, prostate tumor
3585 clinical trials for this condition and its sub-types, 124 tagged with Prostate neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Prostate neoplasm
-
Prostate cancer 1,913 trials · 2,217 incl. sub-types
5 sub-types
- Prostate carcinoma 394 trials · 1,321 incl. sub-types Sub-types →
- Prostate cancer, hereditary 1 trial · 4 incl. sub-types Sub-types →
- Malignant prostate phyllodes tumor 0 trials
- Prostate lymphoma 0 trials
- Prostate sarcoma 0 trials Sub-types →
-
Prostate neuroendocrine neoplasm 20 trials · 25 incl. sub-types
1 sub-type
- Prostate small cell carcinoma 9 trials
-
Prostate intraepithelial neoplasia 2 trials
1 sub-type
-
Benign neoplasm of prostate 0 trials
4 sub-types
- Benign prostate phyllodes tumor 0 trials
- Fibroma of prostate 0 trials
- Prostate leiomyoma 0 trials
- Prostatic adenoma 0 trials
-
Prostate phyllodes tumor 0 trials
2 sub-types
- Benign prostate phyllodes tumor 0 trials
- Malignant prostate phyllodes tumor 0 trials
Most studied deeper sub-types
-
New drug combo shows promise for Hard-to-Treat prostate cancer
Disease control Stopped earlyThis study looked at a combination of two drugs, talazoparib and temozolomide, in 16 men with advanced prostate cancer that had spread and stopped responding to hormone therapy. The goal was to find the safest dose and see if the drugs could shrink tumors. The study was completed…
Phase 1/2 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated Aug 26, 2026 00:00 UTC
-
New drug combo for tough prostate cancer shows early promise, but trial halted
Disease control Stopped earlyThis early-phase study tested a combination of two oral drugs, abemaciclib and darolutamide, in 10 men with metastatic castration-resistant prostate cancer that had spread despite standard hormone therapy. The main goal was to check safety and side effects. The trial was terminat…
Phase 1 • Sponsor: Eli Lilly and Company • Aim: Disease control
Last updated Jun 28, 2026 00:00 UTC
-
Promising prostate cancer combo trial halted before results
Disease control Stopped earlyThis phase 2 trial tested two drugs—cabozantinib and abiraterone—together in 54 men with castration-resistant prostate cancer that had spread to bones. The goal was to see if the combination could delay cancer growth. However, the study was stopped early by the sponsor for busine…
Phase 2 • Sponsor: Exelixis • Aim: Disease control
Last updated Jun 27, 2026 08:09 UTC
-
Prostate cancer vaccine trial halted early – did it work?
Disease control Stopped earlyThis study tested a vaccine called PROSTVAC-V/F in 33 men who had their prostate removed due to cancer and were at high risk of the cancer returning. The goal was to see if the vaccine could keep cancer from coming back. The study was stopped early, so results are limited, but it…
Phase 2 • Sponsor: Medical University of South Carolina • Aim: Disease control
Last updated Jun 27, 2026 08:03 UTC
-
New cancer drug trial halted early – what we know
Disease control Stopped earlyThis early-stage trial tested an experimental drug called NUV-868, alone or with other cancer drugs, in 82 adults with advanced solid tumors (including ovarian, pancreatic, prostate, and breast cancers). The goal was to find safe doses and check for early signs of effectiveness. …
Phase 1 • Sponsor: Nuvation Bio Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
Can a lower dose of prostate cancer drug work just as well?
Disease control Stopped earlyThis study looked at whether men with prostate cancer could take a lower dose of the drug abiraterone (combined with prednisone) and still control their cancer. About 50 men who had never taken abiraterone before were enrolled. The goal was to find the smallest dose that still lo…
Phase 1 • Sponsor: University of Chicago • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC
-
New scan spots prostate cancers standard MRI misses
Diagnosis Stopped earlyThis study tested whether a high-resolution PET-MRI scan using a prostate-specific tracer (18F-PSMA) can find cancers that standard MRI might miss. 62 men with prostate cancer considering focal therapy or surgery received both scans, and results were checked with biopsies. The go…
Phase 2 • Sponsor: Alessandro D'Agnolo • Aim: Diagnosis
Last updated Jul 24, 2026 00:00 UTC
-
Prostate cancer treatment may change how men process common sleep aid
Knowledge-focused Stopped earlyThis pilot study looked at how the sleep drug zolpidem (Ambien) is processed in men with prostate cancer before and after they start hormone therapy that lowers testosterone. Researchers compared these results to healthy women, since women are known to have higher drug levels. Th…
Phase 1 • Sponsor: National Cancer Institute (NCI) • Aim: Knowledge-focused
Last updated Jun 28, 2026 00:00 UTC
-
Can a video game teach surgeons to remove prostate cancer?
Knowledge-focused Stopped earlyThis study tested whether an online video simulator helps surgeons learn laparoscopic radical prostatectomy, a surgery for prostate cancer. It enrolled 29 surgeons who were new to the procedure, comparing those who used the simulator to those who did not. The trial was terminated…
Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Knowledge-focused
Last updated Jun 27, 2026 09:07 UTC
-
Blood marker may predict prostate cancer drug response
Knowledge-focused Stopped earlyThis study aimed to see if a substance in the blood called uPAR can help predict how well men with advanced prostate cancer respond to the drug abiraterone. Only 3 men were enrolled before the study was stopped early. The goal was to find a simple blood test that could guide trea…
Sponsor: Kristoffer Rohrberg • Aim: Knowledge-focused
Last updated Jun 27, 2026 08:11 UTC